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Cucurbita Pepo Inhibits Benign Prostatic Hyperplasia Induced by 
Testosterone In SpragueDawley Rats 
 
 
Tania M. Nawfal 
 
 
Abstract 
 
The Cucurbita pepo (pumpkin) seeds are used to treat benign prostatic hyperplasia 
(BPH). This study examines the effects of pumpkin seeds on dihydrotestosterone 
produced from testosterone that induces the hyperplasia of the prostate gland of male 
rats. Hyperplasia was induced by a subcutaneous injection of testosterone that was 
given in the form of Sutanon 3.568 mg/kg body weight. When the increase in the size of 
the prostate was achieved in 30 days, simultaneous oral administration of pumpkin 
seeds with rat chow was given at doses of 10% w/w, 20% w/w, 30% w/w, 60% w/w and 
30% w/w + Xatral 1 mg/kg body weight. Animals were weighed before dissection and 
the influence of testosterone and pumpkin seed on the weight gain of the rats were 
observed. 
Rats were sacrificed at days 12, 24, and 36. The prostate was removed, and weighed 
immediately. Then prostate weight to body weight ratio were calculated. Blood samples 
were collected to examine the effects of pumpkin seeds on blood lipid profile and liver 
enzymes. Results show that pumpkin seeds affect some of the blood lipid test and have 
no significant effect on the amount of sGOT-AST enzyme and ALP, but there is an 
increase in the activity of sGPT-AST enzyme for the groups treated with 60% and 30% 
Xatral. There is no significant influence on the weight gain of rats treated with 
testosterone and pumpkin seeds. Whereas testosterone increases the weight of the 
prostate (p < 0.05), pumpkin seeds at 30% w/w inhibit hyperplasia and has no effect on 
the blood profile test. This result is confirmed by the histopathological studies that show 
that this group has the same appearance of the negative group. There is abundant stoma 
between glandular cells. In addition there is lack of papillary projections into the lumen 
of the glands. In conclusion, pumpkin seeds at 30% w/w can inhibit prostate hyperplasia 
induced by testosterone, and improve the histology of the prostate. 
Keywords: Cucurbita pepo, Sustanon, benign prostatic hyperplasia (BPH), Xatral. 
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CHAPTER ONE 
INTRODUCTION AND LITERATURE REVIEW 
 
1.1- The Prostate Gland and Benign Prostatic Hyperplasia 
The male reproductive gland or prostate is the gland that secretes part of the semen 
which is the fluid that carries sperm during ejaculation (Cohen & Levy, 2002).  It is 
located below the urinary bladder and surrounds the proximal portion of the urethra, 
which is the tube through which urine and semen pass out of the body (Gossel-
Williams, Davis & O’Connor, 2006). 
 
  
 
Figure 1.1 Anatomy of male reproductive 
system (Gerber, 2011). 
Figure 1.2 Location of the Prostate 
Gland (National Kidney and Urologic 
Diseases Information Clearing house, 
2006). 
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The prostate plays an important function during ejaculation because this gland releases 
an alkaline fluid into the urethra where it is mixed with the seminal fluid, and secreted 
from the seminal vesicles. This fluid nourishes and carries sperm from the testes and out 
of the penis (Cohen et al., 2002). McNeal (1988), divided the prostate gland into four 
glandular zones: peripheral, central, transition, and periurethral. 
 
 
Figure 1.3 Anatomy of Prostate Gland (Wasserman, 2006). 
 
The uncontrolled growth of this gland is referred to benign prostatic hyperplasia (BPH) 
(Gossel-Williams et al., 2006). It represents the noncancerous form of the abnormal 
growth of the cell of the prostate (Veeresh Babu, Veeresh, Patil & Warke, 2010).  In 
man, this overgrowth occurs in the transition and periurethral zones (Lepor, 2004).  
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1.2- Causes of BPH 
Benign prostatic hyperplasia (BPH) is the most common disease that affects older men 
(Edwards, 2008). Early development occurs usually after age of 40 years. Its prevalence 
is greater than 50% by age of 60 years, and by age of 85 years. It is as much as 90% 
(Wasserman, 2006). 
Histological BPH is characterized by the presence of discrete nodules in the prostate 
gland that occurs in the periurethral zone. Clinical manifestations of BPH are caused by 
the squeezing of the prostatic urethra leading to a difficulty in urination and inability to 
completely void the bladder, which in turn cause its distension with hypertrophy. The 
major characteristics on which the clinical BPH is identified are: bladder outflow 
obstruction, lower urinary tract symptoms (LUTS), and prostatic enlargement (Edwards, 
2008. The development of BPH is associated with aging and hormonal changes of men 
(Lepor, 2004). In the prostate gland, testosterone which is produced by the testicular 
interstitial cells is converted to dihydrotestosterone. Androgens have been identified as 
the major cause of the disease process. The inhibition of the growth of the prostate 
gland can be reached by the inhibition of the production of dihydrotestosterone (Gossel-
Williams et al., 2006). It has been identified by other studies that there are factors other 
than androgens that might be responsible for the enlargement of the prostate and 
development of BPH (Lepor, 2004). Some studies have demonstrated that many factors 
such as obesity, hypertension, and diabetes that are associated with cardiovascular 
diseases can be considered as risk factors for BPH. For example, the non-insulin 
dependent diabetes mellitus (NIDDM), which involves excessive insulin levels, play a 
direct role in the growth of the prostate (Hammarsten & Hogstedt, 2001). So this type of 
hormone affects positively the development of BPH (Dharmananda, 2001). 
Moreover, The National Kidney and Urologic Diseases Information Clearing house 
states that men produce both testosterone and small amount of the female hormone 
named estrogen throughout their lives. By age the amount of active testosterone in the 
blood decreases, whereas the amount of estrogen increases in the prostate gland. This 
will lead to an increase in the activity of substances, such as dihydrotestosterone, that 
promote cell growth which in turn promotes BPH (NKUDIC, 2006). 
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On the other hand, some hormones lead to the progression of BPH. It has been proven 
by Dharmananda (2001), that men have a lower incidence of BPH if they are affected 
with liver cirrhosis, compared to those who have normal liver function. This could be 
due to the reduction in the metabolism of hormones to compounds that influence BPH. 
Both exercise and moderate alcohol consumption appear to be protective for men 
affected with cardiovascular disease, and BPH (Dharmananda, 2001).  
 
1.3- Symptoms of BPH 
There are two obstructive mechanisms leading to the appearance of BPH. The first is 
the mechanical obstruction of the urethra, which is due to an overgrowth of epithelial 
tissues in the transitional zone of the prostate. The second is the dynamic obstruction, 
which is due to an excess of sympathetic tone in the prostate and bladder neck 
(Mcpartland & Pruitt, 2000). 
The symptoms of the lower urinary tract are many such as: hesitancy, interrupted, or 
weak urine stream caused by decreased force, feeling that the bladder has not emptied 
completely after urination, urgent need to urinate, hematuria or the blood in the urine 
and nocturia (Wilt et al., 1998). There are also many complications of BPH such as the 
urinary tract infections (UTIs) or bladder stones. In addition, bladder catheterization is 
needed if acute urinary retention or complete inability to void occurs (Edwards, 2008). 
 
1.4- Diagnosis of BPH 
The person may notice by himself one of the symptoms of BPH mentioned above or his 
doctor may find during a routine checkup that the prostate is enlarged. Several tests 
were also done to identify the problem and decide whether surgery is needed. The most 
common are the following: (NKUDIC, 2006). 
 
1.4.1- Digital Rectal Examination (DRE) 
In this examination the doctor inserts a gloved finger into the rectum and feels the part 
of the prostate. According to this test, the doctor can have an idea of the size of the 
gland (NKUDIC, 2006). So prostate volume predicts whether the male suffer from 
BPH. The normal prostate volume is 20 to 30 ml, if the prostate volume is greater than 
40 ml; this means that the male might have a certain problem (Edwards, 2008). 
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1.4.2- Rectal Ultrasound and Prostate Biopsy 
Rectal ultrasound is recommended if there is a suspicion of prostate cancer. In this 
procedure, the doctor inserts a probe in the rectum, which directs sound waves at the 
prostate. These sound waves will form on a display screen an image of this gland. Then 
the doctor uses the probe and the ultrasound images to guide a biopsy needle to the 
suspected tumor to determine whether the cells are cancerous. A few pieces of the 
prostate tissues are collected with this needle for examination with a microscope 
(NKUDIC, 2006).  
 
1.4.3- Urine Flow Study 
The urination into a special device can be used to measure how quickly the urine is 
flowing. BPH was suggested if there is a reduction in the flow of the urine (NKUDIC, 
2006). 
 
1.4.4- Cystoscopy 
In this examination, a small tube is inserted into the penis through the opening of the 
urethra. This procedure is done after the introduction of a solution inside the penis that 
arrests all sensation. The cystoscope tube contains a lens and a light system that help the 
doctor see the inside of the bladder and the urethra. Then the size of the prostate is 
determined, and the degree and location of obstruction is identified (NKUDIC, 2006). 
 
1.4.5- Prostate-Specific Antigen (PSA) Blood Test 
The PSA test is a simple blood test that measures the amount of PSA (prostate specific 
antigen) in the bloodstream of the individual. It is the most conclusive test used for the 
early detection of prostate cancer (Strax, 2006). 
Hara et al. (1971), were first who discovered the prostate specific antigen PSA and 
named it γ-seminoprotein. Then Sensabaugh (1978), found that PSA is a protein, having 
a molecular weight of 30 kDa. Recent studies show that PSA is an organ-specific 
enzyme, or protease, produced by the prostate gland and having a molecular weight of 
38 kDa.  This molecule is the most important protein, which can be found in semen and 
the function is to liquefy it (Miteva, Yotov, Georgiev & Fasulkov, 2006). 
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PSA is immunologically specific for prostatic tissue; it is present in normal, begnin 
hyperplastic, and malignant prostatic tissue, in metastatic prostatic carcinoma, and also 
in prostatic fluid and seminal plasma. Elevated serum PSA concentrations have been 
reported in patients with prostate cancer and benign prostatic hypertrophy. It has been 
shown that PSA diffused into the bloodstream from prostate cancer tissue at a much 
higher concentration than from benign prostatic tissue. Previously, digital rectal 
examination (DRE) was used to diagnose most prostate cancer (Loeb & Catalona, 
2008). 
 
1.4.5.1- Elevation of the PSA 
The PSA test should be done before the digital rectal examination (DRE) because PSA 
level can be elevated if prostate gland is touched. Also there are other changes in the 
prostate that can raise the amount of PSA. The most common are: sexual intercourse or 
any ejaculation within 24 hours before the test. Also prostate biopsy increases the 
amount of PSA and keeps this value high for one week. For PSA to return to its normal 
value, it takes a month or more after biopsy (Strax, 2006).  
 
1.4.5.2- Total PSA Measurement 
PSA is used to detect prostate cancer, using a threshold of 4ng/ml as the upper limit of 
normal. If the amount of PSA is greater than 4 ng/ml, further examination is 
recommended such as digital rectal examination DRE, rectal ultrasound and prostate 
biopsy, because this level can indicate a problem with the prostate, such as 
inflammation, infection, enlargement or even cancer if it exceeds 10 ng/ml (Loeb et al., 
2008). 
 
1.4.5.3- Free PSA 
PSA circulates in the bloodstream in two different forms: free (or unbound) form and 
complexed (cPSA) form that is bound to a protein such as α-1-antichymotropsin. BPH 
can be distinguished from prostate cancer by measuring the proportion or the percent of 
PSA circulating in the free form. Catalona et al. (2000), showed that men had prostate 
cancer if their free PSA was less than 10%. Free PSA must be measured in order to 
detect prostate cancer if the total PSA level is between 4-10 ng/ml (Loeb et al., 2008). 
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1.4.5.4- PSA Density  
PSA is produced by prostatic epithelial cells; this means that larger prostate glands 
produce more PSA. In order to differentiate between prostate cancer and benign 
enlargement, PSA level should be evaluated in relation to the size of the prostate. The 
calculation of PSA density (PSAD) is obtained by dividing the PSA level to the prostate 
volume (Loeb et al., 2008). Benson et al. (1992), emphasized that men having prostate 
cancer have PSAD higher than men having BPH. 
 
1.5- Treatment 
When a diagnosis of BPH is determined, the person should be treated. Results have 
shown that early treatment for men having mildly enlarged gland is not recommended 
because the symptoms of BPH can be cleared up immediately, just a regular checkups is 
needed to detect early problems. On the other hand, treatment is recommended urgently 
for men having severe symptoms to avoid complicated problems to patient's health 
(NKUDIC, 2006). Before starting the treatment of BPH, patient must take antibiotics to 
remove any infection in the urinary tract because one of the symptoms of BPH is the 
urinary tract infections (NKUDIC, 2006). 
There are many ways such as the medical and surgical treatment to relieve symptoms of 
BPH. Treatment options include medical treatments such as the pharmacological and 
phytotherapeutic therapies, minimally invasive treatments and surgical treatments 
(Edwards, 2008). 
 
1.5.1- Pharmacological treatment 
The first line to treat men having BPH is the pharmacological treatment (Nix & Carson, 
2007). Several medications are available, the most common are: 5alpha-reductase 
inhibitors and alpha1 blockers or (alpha1-adrenergic antagonists) (Mcpartland et al., 
2000). 
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A) 5 α-Reductase Inhibitors 
In the prostate gland, the conversion of testosterone to dihydrotestosterone by the 
enzyme 5 α-reductase promotes the growth of the prostate (Edwards, 2008). Reducing 
the androgenic stimulation of the prostate gland is considered as one of the 
pharmacological treatment of BPH (Matzkin, Chayen, Goldfarb, Gilad & Braf, 1992). 
The most common 5 α-reductase inhibitors are Finasteride (Proscar) and dutasteride 
(Avodart) which suppress prostate growth by inhibiting the conversion of testosterone 
to dihydrotestosterone. They are beneficial if the prostate volume is greater than 40 ml 
(Edwards, 2008). Matzkin et al. (1992), showed that the 5 α - and 5 β-reductases 
metabolize the two hormones testosterone and androstenedione to their conjugates 
androsterone (A) and etiocholanolone (E), that are excreted in the urine. They showed, 
that in normal men the ratio of A/E is 1.5 due to the high activity of α –reductase, but in 
men suffering from BPH and treated with 5 α -reductase inhibitor, the ratio of A/E 
decreases to less than 0.5. To achieve clinical benefit, the 5-alpha reductase inhibitors 
are recommended for six to 12 months because they do not relieve symptoms 
immediately (Edwards, 2008). Moreover, it was shown that, 5-alpha reductase inhibitors 
reduce the risk of acute urinary retention (Edwards, 2008), but at the same time, they 
caused adverse effect for men such as decreasing ejaculate volume, libido, and sexual 
erectile dysfunction (Nix et al., 2007). 
Andriole et al. (1998), showed that patients treated using 5-alpha reductase inhibitors, 
have a high risk of prostate cancer because they do lower PSA blood level; which is a 
substance used to detect prostate cancer. To correct this effect, we should double the 
value of the measured PSA when screening for prostate cancer. 
 
B) Alpha1 Blockers 
The constriction of the prostatic urethra is due to the contraction of the smooth muscles 
of the prostate gland which is stimulated by alpha1-adrenergic receptor. To promote the 
relaxation of the smooth muscle of the prostate and urethra, alpha blockers or alpha1-
receptor antagonists is the most effective to relieve the symptoms of lower urinary tract 
for men having moderate to severe BPH (Edwards, 2008).  Therefore they work by 
relaxing the smooth muscle and not by reducing the size of the prostate (Blanchard & 
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Abu-Baker, 2010). Thus the mechanism that leads to the relaxation of this smooth 
muscle is to inhibit norepinephrine from binding to alpha1-adrenergic receptor, by 
inhibiting alpha1-adrenergic receptors (Roehrborn & Schwinn, 2004). The alpha1-
adrenergic antagonists are: prazosin, terazosin, doxazosin, alfuzosin, and tamsulosin 
(Blanchard et al., 2010). Three of them, such as prazosin, terazosin, doxazosin are used 
to treat hypertension. They act on vascular smooth muscles thereby lowering blood 
pressure. On the other hand, alfuzosin and tamsulosin have minimal or no effect on 
blood pressure, so they are more selective to treat the constriction of the smooth 
muscles of the prostate and urethra (Edwards, 2008). In addition Nix et al. (2007), 
showed that alpha blockers are more selective than other agents, especially for men who 
need to preserve the sexual function. They demonstrated that alfuzosin preserves the 
function of ejaculation and tamsulosin has the effect to induce ejaculation. 
 
B.1 Xatral or Alfuzosin hydrochloride 
Chemical Name: (R, S)-N-[3-[(4-amino-6, 7-dimethoxy-2-quinazolinyl) 
methylamino]propyl] tetrahydro-2-furancarboxamide hydrochloride 
Molecular Formula: C19H27N5O4•HCl 
Structural formula: 
 
Figure 1.4 Structural formula of Alfuzosin hydrochloride (Roehrborn, Van Kerrebroeck 
& Nordling, 2003).  
 
Each Xatral tablet contains 2.5 mg of the active ingredient alfuzosin hydrochloride. 
Alfuzosin hydrochloride is a crystalline powder having a white to off-white color and 
melts at 240°C. It is readily soluble in water (Nordling, 2005). In addition this tablet 
contains microcrystalline cellulose, lactose, povidone, sodium, starch glycollate, 
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magnesium stearate, hypromellose, Macrogol 400, and titanium dioxide (Roehrborn et 
al., 2003). Alfuzosin is used for the treatment of moderate to severe BPH. It removes 
the lower urinary tract symptoms and has no effect on blood pressure and the 
ejaculatory function. It is classified as an alpha 1-adrenergic antagonist (Lee, 2003). The 
contraction of the smooth muscle is due to the presence of alpha-1 receptors. There are 
three subtypes of alpha-1 receptors: alpha-1a, alpha-1b, and alpha-1d. The contraction 
of the smooth muscle of the prostate is mediated by alpha-1a receptors while the others 
are involved in the contraction of the vascular muscle. Alfuzosin is an agent specific 
that is involved in the inhibition of alpha-1a receptors; this will lead to the relaxation of 
the smooth muscle in the prostate, bladder neck, and urethra (Langer, 1999). Alfuzosin 
is recommended twice or thrice daily when using the immediate-release (IR) 
administration. When using the extended-release (ER) administration, it is 
recommended once- or twice-daily. This formulation produces small differences 
between peak and in the level of the drug in serum because the administration of the 
drug is continuous over the time. This will explain why a fewer frequency of 
cardiovascular adverse effects occur when using ER versus IR alfuzosin. For the 
management of benign prostatic hyperplasia (BPH), the recommended adult dosage of 
alfuzosin hydrochloride is 10 mg once daily which is safe and effective even if it is 
administered to patients over the age of 65 years. No titration is needed for this dosage 
and within few days of treatment its onset of peak action begins (Lee, 2003). 
In addition, Alfuzosin has many side effects such as: headache, dizziness, fatigue and 
upper respiratory tract infection (Roehrborn et al., 2004).  Alfuzosin should not be used 
in patients with renal insufficiency, and liver failure (Van Kerrebroeck, Jardin, Laval & 
Van Cangh, 2000). As conclusion, alfuzosin 10 mg is recommended for men with lower 
urinary tract symptoms to improve the erectile function while preserving the ejaculatory 
function (Rosen, Seftel & Roehrborn, 2007).  
 
C) Combination therapy 
The combination of the two drugs, the 5 α-Reductase inhibitors and the alpha-
adrenergic antagonists increase the efficacy to remove the symptoms of BPH instead of 
using each drug alone, or doing the surgery (McConnell et al, 2003). 
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1.5.2- Phytotherapeutic treatment 
 
In the 15
th
 century, the Egyptians were the first people who use the plant extract to treat 
BPH. This type of treatment is called phytotherapeutic treatment. After that, it was 
known in Europe, and the western hemisphere. In Italy, phytotherapy represents half the 
medications to treat BPH, compared to 5 α -reductase inhibitor and alpha blockers that 
represent 10%. In the United States, phytotherapies can be used as dietary supplements 
without prescription to treat BPH. So the phytotherapeutical agents are used to treat 
mild to moderate symptomatic BPH (Wilt et al., 1998). The most common herbal 
preparations used to treat BPH are: Serenoa repens, Saw palmetto, Pygeum africanum, 
Tadenan, Cernilton, and hypoxis rooperi, (Dedhia, 2008). In addition, coconut oil, urtica 
dioica radix (nettle root), pinus pinea, cucurbita pepo (pumpkin), and secale cereale are 
used. The combination extracts of two or more plants can also be used (Dreikorn, 2007). 
 
1.5.2.1- Pumpkin or Cucurbita Pepo 
In developing countries, people use dietary plants and herbal preparations as a 
traditional medicine. Pumpkin is one of the plants, which are used as medicine or 
functional food to treat many diseases.  
 
Figure 1.5 Pumpkin or Cucurbita pepo (Winters, 2011). 
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The family of pumpkin is Cucurbitaceae. It is divided into Cucurbita pepo, C. 
moschata, C. maxima, C. mixta, C. ficifolia and C. telfairia. 
Cucurbita pepo, C. maxima, and C. moschata, are the most important species because 
they have a great productivity which make them worldwide cultivated (Caili, Huan & 
Quanhong, 2006). The pumpkin plant belongs to the dicotyledonous seed vegetable. It 
is an annual herb or vine. It is made of a flexible stem with trifoliate leaves. When 
pumpkin matures, yellow flowers then large fruits appear. Each fruits contain numerous 
seeds (Caili et al., 2006). Those seeds have an oval flat shape, and a greenish dark color 
(Abdel-Rahman, 2006).  
 
 
Figure 1.6 Flower and Leave of 
Cucurbita Pepo (Danos, 1989). 
 
Figure 1.7 Seeds of Cucurbita Pepo 
(Danos, 1989). 
 
 
1.5.2.2- Phytochemistry 
Pumpkin seeds contain the biologically active components such as: polysaccharides, 
para-aminobenzoic acid, γ-aminobutyric acid and carotenoid (Caili et al., 2006). They 
are considered as a good source of vitamins A, B, and E (Gossel-Williams et al., 2006). 
Four isomers of vitamin E are found: γ-and α-tocopherol which are present at high 
amount and β-and δ-tocopherol which are present at low amount (Murkovic, Hillebrand, 
Draxl, Pfannhauser & Winkler, 1999). It has been identified, that vitamin E inhibits the 
growth of the prostate cell by regulating the cell cycle mechanisms and apoptosis (Uzzo, 
et al. 2004). Moreover pumpkin seeds have a physiological effect due to the presence of 
proteins, antioxidants, oil and fiber which is found in the cell wall of the seeds 
(Kostalova, Hromadkova & Ebringerova, 2009). Those seeds are considered also as a 
high source of energy due to the presence of 40 to 50 % lipids and 30 to 37% proteins of 
the dry material (Caili et al., 2006). Four fatty acids are found in the pumpkin seeds. 
 13 
The unsaturated fatty acids are dominant over the saturated one. Those acids are 
distributed in the following percentage: (8.0%) stearic acid C18:0, (13.3%) palmitic acid 
C16:0, (29.0%) oleic acid C18:1 and (47.0%) linoleic acid C18:2. These four fatty acids 
represent around 98 % of the total amount. The rest of the fatty acids are found at a 
level below 0.5 % (Younis, Ghirmay & Al-Shihry, 2000). Pumpkin seeds are also rich 
in phytosterols, which is of special interest because it is responsible to lower the serum 
cholesterol. Of those sterols, Δ7- sterols is the main one which is rare in other plant 
seeds, and Δ5- sterols and Δ8- sterols are also found (Murkovic, Piironen, Lampi, 
Kraushofer & Sontag, 2004). In addition, pumpkin seeds contain the chemical elements 
such as potassium, phosphorus, calcium, chromium, copper, magnesium, manganese, 
selenium, molybdenum, sodium, iron and zinc which is the most useful element in 
treating the enlargement of the prostate (Glew et al., 2006). Zinc inhibits the overgrowth 
of the prostate, by inhibiting NF-kB which is the transcriptional factor that is 
responsible for the survival of the cell (Uzzo et al., 2004). 
 
1.5.2.3- Uses of Pumpkin or Cucurbita Pepo 
 
Pumpkin is used as antidiabetic, antihypertensive, antibacterial, antitumor, 
antihypercholesterolemia (regulate cholesterol level), intestinal antiparasitia (fight 
against intestinal worms and parasites), anticancer, antiinflammation and 
immunomodulation (Caili et al., 2006). Pumpkin seeds are also used as anti-depressing 
agent, due to the presence of L-tryptophan (Eagles, 1990).  Pumpkin seeds can lower 
the risk of bladder-stone disease due to the presence of high amount of phosphorus 
(Suphakarn, Yarnnon & Ngunboonsri, 1987). Studies show that the pumpkin seed oil is 
used to treat BPH by inhibiting the production or the action of dihydrotestosterone 
produced from testosterone that induces the hyperplasia of the prostate gland (Gossel-
Williams et al., 2006). Moreover, the Δ7- phytosterols together with their glycosides, 
which are found in the seeds, inhibit the action of the enzyme 5 α-reductase due to their 
similarity to testosterone. Thus Δ7- phytosterols relieve the symptoms of BPH by 
reducing the concentrations of dihydrotestosterone (Mandl, Reich & Linder, 1999). 
Another study shows that, phytosterols interfere with the actions of dihydrotestosterone 
thus blocking the androgen receptor. Thus, pumpkin seed oil improves urinary function 
and relieves the symptoms of BPH because it has a direct influence on the prostate size 
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(Gossel-Williams et al., 2006). Tsai et al. (2006), show that pumpkin seed oil combined 
with Phytosterol-F can block the testosterone prazosin-induced (T-P) increases in the 
ratio of prostate weight to body weight. 
 
1.5.3- Surgical Treatments 
If medical treatments fail, surgical treatment is needed to remove the obstruction and 
incomplete voiding caused by BPH. There are many types of surgery such as the 
transurethral resection of the prostate, transurethral incision of the prostate, open 
surgery, and laser prostatectomy (Edwards, 2008).  
1.5.3.1 Transurethral Resection of the Prostate (TURP) 
It is used to reduce the pressure on the urethra, due to the enlargement of the prostate 
gland. It is performed under anesthesia. The urologist inserts through the urethra an 
instrument called a resectoscope that contains an electrical loop to remove pieces of 
prostate tissue (NKUDIC, 2006). There are many complications of TURP such as 
sexual dysfunction where the semen flow backward, hemorrhage, and strictures  
(NKUDIC, 2006). 
1.5.3.2 Transurethral Incision of the Prostate (TUIP) 
This technique is used to widen the urethra by reducing the pressure caused by the 
prostate. In this procedure, the doctor makes a cut in the neck of the bladder and in the 
prostate instead of removing the tissue such as TURP. It has less complication on the 
retrograde ejaculation (NKUDIC, 2006). 
1.5.3.3 Open Surgery 
When the prostate gland is large, open surgery is made to remove the inner core of the 
prostate by making an incision in the skin of the lower abdomen (NKUDIC, 2006). 
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1.5.3.4 Laser Prostatectomy 
Several studies show that Holmium laser enucleation of prostate (HoLEP) is more 
effective and safe than TURP for BPH patients. It has no role when the prostate has a 
large volume (Naval, Saurabh & Aneesh, 2006). It relieves the symptoms of BPH by the 
energy released from the laser that destroys the prostate tissue (NKUDIC, 2006). 
 
 
 
  
 16 
CHAPTER TWO 
MATERIALS AND METHODS 
 
2.1- Animals Preparation 
All experiments were performed on adult Male Sprague-Dawely rats bred in the animal 
room of the biology department at the Lebanese American University. The rats were 
housed in a controlled environment in stainless steel wire- bottom cages at a 
temperature of 21+ 2 ºC, and humidity of 40-60% with 12 hours photoperiod, during the 
whole study. Standard rat chow food (Laboratory rodent starter diet no. 1, Hawa 
Chicken Co., Lebanon) and tap water were given ad libitums. 
 
2.2- Sources of pumpkin seeds 
The pumpkin seeds were purchased from local Lebanese roastry. The seeds were plain 
without shells. No heating treatment was applied to the seeds. 
 
2.3- Animals groups 
One hundred twenty (120) Sprague Dawley rats were used in this experiment. Rats were 
divided into eight groups:  
1) 15 rats as negative control, were kept growing normally, during the period of the 
study, without being injected with Sustanon (testosterone). 
2) 15 rats as positive control were injected, every ten days, with Sustanon 3.568 
mg/kg body weight and fed on chow diet. 
3) 15 rats were injected with sustanon, and then treated with Xatral 1 mg/kg body 
weight. 
The other groups were also injected, every ten days, with Sustanon 3.568 mg/kg body 
weight. Before each injection, two rats from the negative control and the positive 
control were removed and weighed. After sacrifying, prostates were also removed and 
weighed. Prostate weight over body weight was calculated in order to compare the two 
different groups.  After 30 days, we realized that the increase in size of the prostate was 
achieved; treatment begins using different dosages of pumpkin seeds. 
4) 15 rats were treated with 10% w/w of food pepo.  
5) 15 rats were treated with 20% w/w of food pepo.  
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6) 15 rats were treated with 30% w/w of food pepo.  
7) 15 rats were treated simultaneously with both 30% w/w of food pepo and Xatral.  
8) 15 rats were treated with 60% w/w of food pepo.  
 
2.4- Inducing BPH with Sustanon 
Hyperplasia of the rat prostate was induced by a subcutaneous injection of testosterone 
which was given in the form of Sustanon 3.568 mg/kg body weight, dissolved in 
ordinary olive oil. It is an oil-based injectable containing four different testosterone 
combinations which are: testosterone propionate, 30 mg; testosterone phenylpropionate, 
60 mg; testosterone isocaproate, 60mg; and testosterone decanoate, 100 mg (Roberts, 
2010).  
 
2.5- Dilution of Sustanon 
Put 149 ml of olive oil in a 300 ml Erlenmeyer flask. Seal the tube with cotton. Fill a 
500 ml beaker with tap water and then heat it.  After that, put the tube in the beaker that 
contains the boiling water. Allow sterilization of Olive oil for 15-20 minutes. Finally 
allow the tube to cool. Then add the 1ml Sustanon 250 mg/ml to the sterilized olive oil 
and vortex them. Always work near a flame (Aseptic conditions).  
 
2.6- Injection of Sustanon and treatment 
The diluted appropriate volume was injected to rats intraperitoneally:  the 
administration of materials into the peritoneal cavity should be done into the space 
surrounding the abdominal organs, avoiding the injection directly into an organ. Rats 
should be restrained with their abdomen exposed and their head held downwards, this 
causes the freely moveable abdominal organs to move towards the animal’s diaphragm 
making accidental puncture of organs less likely.  
Treatments with pepo were done for 12, 24 and 36 days. It was given simultaneously 
with their foods. For the group treated with Xatral, rats were fed on their chow diet and 
Xatral 1mg/kg body weight was included in the drinking water. On the day of each 
treatment with pepo, all the rats of each group were weighed. Calculation was also done 
for the amount of each dose and percentage that must be given for each group according 
to the average body weights knowing that each rat consumes 7g/100g body weight. 
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2.7- Sample collection and Blood study 
Each twelve days, five out of fifteen rats from the above groups were sacrificed, after 
sedating them with ether. Anesthesia was maintained by the use of a nose cone. Stretch 
the rat out in the supine position in the dissection tray. Make a midline incision through 
the skin from the pubic region to the tip of the lower jaw. Make a midline incision 
through the abdominal wall musculature from the pubic symphysis to the lower edge of 
the sternum. Proceed by isolating the following organs: prostate and liver. Livers were 
removed to be sure that the treatment doesn’t affect it. Prostate glands were also 
removed and weighed. Then calculation of the prostate gland over body weight was 
done. 
While dissecting, 10 ml of blood samples were aspirated with a syringe from the 
inferior vena cavae of the rats. To collect the serum, tubes were incubated at room 
temperature for 30 minutes to clot then centrifuged at a speed of 5000X (rpm) for 20 
minutes. Some of the serum was placed in Eppendorf tubes for direct liver enzyme 
analysis: GOT-AST, GPT- AST, and ALP. The remaining samples were collected in 
Eppendorf tubes and stored in deep freeze for subsequent analyses. Samples stored were 
later used to assess triglycerides, glucose, cholesterol, and HDL-Cholesterol, using 
appropriate SPINREACT kit. 
 
2.8- Prostate weight to body weight ratio 
Animals were weighted before dissection. After scarifying, prostates were removed and 
weighed immediately after blotting them dry of excess fluids.  Then prostate weight to 
body weight ratio were calculated. 
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2.9- Calculation of the Percentage of inhibition 
a) Prostate weight 
b) Prostate weight/ body weight  
 
Then percentage of inhibition was calculated as follows: 









 100
control negativecontrol positive
control negativegroup treated
100  
 
Serum Assays 
 
 
2.10- Determination of serum Glucose 
Principle 
The glucose is determined after enzymatic oxidation in the presence of glucose oxidase. 
The hydrogen peroxidase formed reacts under catalysis of peroxidase with phenol and 
4-aminophenazone to form a colored compound. 
Glucose in serum is measured based on the following enzymatic reactions: 
Glucose + O2 + H2O      GOD                       Gluconic acid + H2O2 
 H2O2 + Phenol +Aminophenazone       POD                  Quinone + H2O 
 
The intensity of the red-violet dye formed at the end of the reaction is propotional to the 
glucose concentration and is measured by spectrophotometry at a wavelength at 505 
nm. 
GOD: glucose oxidase; POD: Peroxidase 
 
Procedure 
Samples, run in duplicates, were mixed with the working reagent, and incubated for 10 
minutes at 37ºC. The absorbance (A) of the samples and the standard are measured 
against the reagent blank at λ = 505 nm (Heλios-γ spectrophotometer, UVG 101103. 
UK) 
 
Calculation 
Concentration of the sample (mg/ dl) = 
standard  theof Abs.
sample  theof Abs.
 Conc. of the standard 
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Glucose standard is 100 mg/dl concentration according to the manufacturer’s leaflet 
(SPINREACT). 
 
2.11- Determination of Serum TAG 
Principle 
The TAG assay kit (spinreact), used is based upon a colorimetric method. The TAG are 
enzymatically hydrolyzed to glycerol and free fatty acids. The glycerol liberated reacts 
with Glycerol Kinase (GK) and Glycerol-3-Phosphate Oxidase (GPO) yielding H2O2. 
The H2O2 concentration is determined through the Trinder’s reaction. The enzymatic 
reaction sequence employed in the assay was as follows: 
Triglycerides + H2O          
LPL
               Glycerol + Fatty Acids 
Glycerol + ATP              
GK
                  Glycerol-3-phosphate +ADP 
Glycerol-3-phosphate + O2              
GPO
                Dihydrooxyacetone-P + H2O  
H2O2 + 4-AP + p- Chlorophenol         
POD
                Quinonimine + H2O 
 
The intensity of the ended red dye formed is proportional to the concentration of 
triglycerides in the sample   and can be determined by spectrophotometer at a 
wavelength = 505 nm. 
   
Procedure 
Samples, along with standards, were run in duplicates, and were mixed with the 
working reagent and incubated for 10 minutes at room temperature. The absorbance (A) 
of the unknown and the standard samples were measured against Blank reagent at λ = 
505 nm (Heλios-γ spectrophotometer). Color of the mixtures was varying from light 
pink to dark red, and it was stable for about 30 minutes. 
 
Calculation 
Concentration of triglycerides (mg/ dl) in the sample = 
standard  theof Abs.
sample  theof Abs.
  Conc. 
of the standard. 
Triglycerides standard is 200 mg/dl concentration according to the manufacturer’s 
leaflet (SPINREACT). 
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2.12- Determination of Serum Cholesterol 
Principle 
The cholesterol assay kit (Spinreact, S.A, Spain) used was based upon a colorimetric 
method. Cholesterol and its esters are released from lipoproteins by detergents. 
Cholesterol esterase hydrolyses the esters and is formed in the subsequent enzymatic 
oxidation of cholesterol by cholesterol- oxidase according to the following reactions: 
Cholesterol Esters + H2O        
CHE
              Cholesterol + Fatty Acids 
Cholesterol + O2              
CHDE
                4- Cholestenoma + H2O2    
2 H2O2 + Phenol + 4-Aminophenazone        
POD
              Quinonimine + 4 H2O 
 
The resulted Hydrogen peroxide forms a red dye. The color intensity is proportional to 
the cholesterol concentration in the sample that can be determined using the 
spectrophotometer at a wavelength λ = 505 nm. 
 
Procedure 
Samples, along with standards, were run in duplicates, and were mixed with the 
working reagent and incubated for 10 minutes at room temperature. The absorbances of 
the samples and the standard samples were measured against Blank reagent at λ = 505 
nm (Heλios-γ spectrophotometer). Color of the mixtures was varying from light pink to 
dark red, and it was stable for about 30 minutes. 
 
Calculation 
Concentration of cholesterol (mg/ dl) in the sample = 
standard  theof Abs.
sample  theof Abs.
 Conc. of 
the standard. 
Cholesterol standard is 200 mg/dl concentration according to the manufacturer’s leaflet 
(SPINREACT). 
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2.13- Determination of Serum HDL-Cholesterol 
Principle 
Very low density lipoprotein (VLDL) and low density lipoprotein (LDL) in the serum 
are precipitated by phosphotungstate in the presence of magnesium ions and can be 
removed by centrifugation where high density lipoprotein remain in the supernatant. 
Determination of HDL cholesterol is performed using the clear supernatant. 
 
Procedure 
0.5 ml of the serum sample is mixed with 50 μl of the precipitating reagent (14 mmol/L 
phosphotungstic acid with 2 mmol/L magnesium chloride). Then, samples were 
incubated for 10 minutes at room temperature, followed by centrifugation at 12000 rpm 
for 4 minutes. The clear supernatant was used for cholesterol determination using the 
cholesterol assay kit as described in the previous section and the absorbance of the 
samples is measured by spectrophotometry at λ = 505 nm. 
 
Calculation 
HDL- cholesterol concentration was estimated according to the following equation: 
HDL- cholesterol (mg/dl) = Absorbance of the sample  320 at λ = 505 nm. 
 
2.14- Determination of serum LDL-Cholesterol 
Concentration of LDL cholesterol was determined according to the Friedwald equation: 
LDL cholesterol = Total Cholesterol – (TAG/5) – HDL Cholestrol 
 
2.15- Determination of Serum GOT-AST 
Principle 
Aspartate aminotransferase (AST) or glutamate oxaloacetate (GOT) is one of the liver 
enzymes that catalyses the reversible transfer of an amino group from aspartate to α-
ketoglutarate. Then the oxalacetate formed will be reduced to malate by malate 
dehydrogenase (MDH) and NADH as follows: 
Aspartate + α-ketoglutarate         AST                   Glutamate + Oxalacetate 
Oxalacetate + NADH + H 
+              
 
MDH              
 Malate + NAD
+
 
 23 
Using the spectrophotometer, the rate of decrease in concentration of NADH is 
measured at a wavelength = 340 nm. This decrease in the concentration of NADH is 
propotional to the catalytic concentration of AST found in the sample. 
 
Procedure 
100 μl of each sample are mixed with 1 ml of the working reagent and incubated at a 
temperature of 25 ºC -30ºC  for 1 minute, after which the extinction decrease (ΔA) is 
measured at λ = 340 nm (Heλios-γ spectrophotometer) against distilled water every 1 to 
3 minutes. 
 
Calculation 
1750(min)
A
 (U/L)activity  sGOT


  
 
2.16- Determination of Serum GPT-AST 
Principle 
Alanine aminotransferase (ALT) or glutamate pyruvate transaminase (GPT) is another 
liver enzyme that catalyses the conversion of amino acids to the corresponding α-keto 
acids through the transfer of an amino group. GPT is determined based on the following 
enzymatic reactions: 
Alanine + α-ketoglutarate         ALT                   Glutamate + Pyruvate 
Pyruvate + NADH + H 
+              
 
LDH                  Lactate + NAD
+
 
Using the spectrophotometer, the rate of decrease in concentration of NADH is 
measured at a wavelength = 340 nm. This decrease in the concentration of NADH is 
proportional to the catalytic concentration of ALT found in the sample. 
* LDH: Lactate dehydrogenase. 
 
Procedure 
100 μl of each sample are mixed with 1 ml of the working reagent and incubated at a 
temperature of 25 ºC -30ºC for 1 minute, after which the extinction decrease (ΔA) is 
measured at λ = 340 nm (Heλios-γ spectrophotometer) against distilled water every 1 to 
3 minutes. 
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Calculation 
1750(min)
A
 (U/L)activity  sGOT


  
 
 
2.17- Determination of Serum ALP 
Principle 
Alkaline Phosphatase is measured based on the following reaction: 
P-nitrophenyl-phosphate       
ALP
             p-nitrophenol + phosphate    
 
Procedure 
20 μl of each sample are mixed with 1.2 ml of the working reagent and incubated at a 
temperature of 25 ºC 30ºC for 1 minute, after which the extinction decrease (ΔA) is 
measured at λ = 405 nm (Heλios-γ spectrophotometer) against distilled water every 1 to 
3 minutes. 
 
Calculation 
3003(min)
A
 (U/L)activity  ALP


  
 
 
2.18- Histology 
The tissues of the prostate glands were microscopically examined, after being fixed and 
preserved in 10% neutral formalin, processed and trimmed, embedded in paraffin, 
sectioned with a paraffin microtome to produce tissue sections of about 4-10 
micrometers in thickness. Those sections which are colorless were stained to distinguish 
the histological elements of the tissue. Hematoxylin is a basic dye which is used to 
stains acidic structures purplish blue. So the nucleus, ribosomes, and rough endoplasmic 
reticulum are stained blue. In contrast eosin is an acidic dye which stains basic 
structures red or pink. The cytoplasmic proteins are basic, so they are stained with 
eosin. Periodic Acid Shicff (PAS) is used to stain basement membrane, and 
glycoprotein. To produce permanent slides, tissue sections were covered by a natural or 
synthetic mounting medium named balsam. This is followed by covering the slides with 
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a clean cover slip that is laid down on the slide and is left to dry. A complete 
histopathologic examination was performed, and then images of all slides were 
classified to be presented in the results.  
 
2.19- Statistical Analysis 
All results were expressed as mean ± S.E.M. Statistical Analysis was performed using 
student t-test to compare any two group together. A (p) value of less than 0.05 was 
considered to be significant.  
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CHAPTER THREE 
RESULTS 
 
3.1- Serum Lipid Profile 
The tables below summarize the mean serum concentration values in mg/dl of glucose, 
triglycerides, cholesterol, HDL-Cholesterol, and LDL- Cholesterol, in positive control 
and groups treated with pumpkin seeds for the three different dissections. 
 
3.1.1- Serum Glucose 
There was an increase in the concentration of serum glucose of the groups Xatral, 10%, 
20% and 30% pepo in the first and second dissection. There was also an increase in the 
groups 60% pepo, and 30% pepo + Xatral in the second and third dissection with 
respect to the negative group. On the other hand, there was a significance increase in the 
concentration of serum glucose of the groups 20% pepo and 30% pepo (trird dissection), 
whereas there was a decrease in the concentration of the groups 60% pepo, and 30% 
pepo + Xatral with respect to the positive group.  
 
Table 3.1.1 Glucose concentrations in serum after 12, 24 and 36 days for testosterone 
treated rats consuming different doses of pepo and Xatral. Values denote mean ± S.E.M. 
(n = 5) 
Glucose 12 Days 24 Days 36 Days 
Negative control 85.72 ± 6.48 86.4 ± 8.43 84.86  ± 11.32 
Positive control 227.49 ± 25.83 193.37 ± 18.31 75.98 ± 5.51 
Xatral 169.57 ± 16.96
 b
 146.75 ± 16.20
 b
 91.71 ± 12.20 
10% pepo 200.63 ± 13.61
 b
 157.57 ± 5.51
 b
 94.74 ±8.32 
20% pepo 221.06 ± 20.48
 b
 146.92 ± 11.80
 b
 111.41 ± 14.23 ª 
30% pepo 194.89 ± 11.96
 b
 168.11 ± 10.34
 b
 97.62 ± 11.56 ª 
60% pepo 88.04 ± 4.90
 
ª
 
 98.24 ± 6.34 ª
 
 136.97 ± 16.72 ª
 b
 
30% pepo + Xatral 87.05 ± 6.01
 
ª 186.86 ± 44.50
 b
 124.83 ± 10.64 ª
 b
 
 
ª Significant difference (p < 0.05) with respect to the positive control 
b 
Significant difference (p < 0.05) with respect to the negative control 
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3.1. 2- Serum Triglyceride 
Results showed an increase in the concentrations of the circulating TAG of the groups 
Xatral (first dissection), 20% (second and third dissection), 30% pepo (second 
dissection) with respect to the negative group. There was also an increase in the second 
and third dissection for the groups 60% pepo (first dissection), and 30% pepo +Xatral 
(first and second dissection). 
Whereas a significant decrease in the concentrations of the circulating TAG was 
observed in the groups: 10% pepo (first dissection), 30% pepo, and 30% pepo + Xatral 
with respect to the positive group. There was no significant difference among the other 
groups. 
 
Table 3.1.2 Triglyceride concentrations in serum after 12, 24 and 36 days for 
testosterone treated rats consuming different doses of pepo and Xatral. Values denote 
mean ± S.E.M. (n = 5) 
Triglyceride 12 Days 24 Days 36 Days 
Negative control 62.5 ± 8.51 62.67 ± 9.30 62.76 ± 10.87 
Positive control 137.10 ± 14.71 47.18 ± 8.22 78.47 ± 9.18 
Xatral 91.40 ± 26.75
 b
 43.06 ± 3.73 57.94 ± 7.22 
10% pepo 66.28 ± 15.67 ª 54.35 ± 7.37 68.87 ± 9.61 
20% pepo 99.00 ± 27.95
 b
 61.85 ± 11.44 94.78 ± 8.36 
b
 
30% pepo 54.67 ± 11.72 ª    91.93 ± 10.84 ª
 b
 78.15 ± 7.54 
60% pepo 126.12 ± 21.60
 b
 66.33 ± 10.43 71.19 ± 0.65  
30% pepo + Xatral 102.37 ± 24.7
 b
 104.17 ± 8.46 ª
 b
 40.32 ± 0.01 ª
 
 
 
ª Significant difference (p < 0.05) with respect to the positive control 
b 
Significant difference (p < 0.05) with respect to the negative control 
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3.1. 3- Serum Cholesterol  
There was a significant decrease in the concentrations of circulating cholesterol of the 
groups 60% pepo, and 30% pepo + Xatral with respect to the negative group. 
Also with respect to the positive group, there was a significant decrease of the groups: 
20% pepo (first dissection), 30% pepo (first dissection), 60% pepo, and the 30% pepo + 
Xatral. No significant difference was observed among the other groups.  
 
Table 3.1.3 Cholesterol concentrations in serum after 12, 24 and 36 days for 
testosterone treated rats consuming different doses of pepo and Xatral. Values denote 
mean ± S.E.M. (n = 5). 
 
Cholesterol 12 Days 24 Days 36 Days 
Negative control 85.90 ± 6.15 84.34 ± 6.81 83.09 ± 7.98 
Positive control 92.08 ± 4.20 87.27 ± 15.25 86.98 ± 5.99 
Xatral 98.06 ± 8.52 95.13 ± 13.55 76.77 ± 9.90 
10% pepo 79.41 ± 7.98 98.65 ± 11.67 77.95 ± 4.53 
20% pepo 66.16 ± 5.62 ª
 
 66.52 ± 9.84 77.17 ± 10.72 
30% pepo 67.92 ± 7.64 ª 88.68 ± 6.84 73.35 ± 1.64 
60% pepo 55.84 ± 8.83 ª
 b
 39.94 ± 8.06 ª
 b
 47.65 ± 6.42 ª
 b
 
30% pepo + Xatral 65.92 ± 8.78 ª
 b
 58.59 ± 5.34
 b
 56.01 ± 2.72 ª
 b
 
 
ª Significant difference (p < 0.05) with respect to the positive control 
b 
Significant difference (p < 0.05) with respect to the negative control 
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3.1. 4- Serum HDL-Cholesterol 
Compared to the negative group, there was a significant increase in the concentrations 
of circulating HDL-Cholesterol among the groups: Xatral (third dissection), 60% pepo 
and 30% pepo + Xatral (first dissection). In addition, there was a decrease of the groups 
20% pepo (third dissection), 60% pepo and 30% pepo + Xatral (second and third 
dissection). 
More a decrease was observed in the concentrations of circulating cholesterol of the 
groups:  10% and 20% pepo (third dissection), 30% and 60% pepo (second and third 
dissection), and the 30% pepo + Xatral (third dissection) with respect to the positive 
group. No significant difference was observed among the positive group and Xatral 
group compared to the negative group.  
 
Table 3.1.4 HDL-Cholesterol levels in serum after 12, 24 and 36 days consumption of 
different doses of pepo and Xatral in testosterone treated rats. Values denote mean 
± S.E.M. (n = 5) 
HDL – Cholesterol 12 Days 24 Days 36 Days 
Negative control 32.17 ± 2.89 31.65 ± 2.39 30.05 ± 3.07 
Positive control 32.10 ± 8.91 24.70 ± 3.71 50.94 ± 3.35 
Xatral 23.68 ± 0.29 31.42 ± 3.15  46.98 ± 0.41
 b
 
10% pepo 36.80 ± 2.11 32.32 ± 4.65 27.94 ± 2.18
 
ª 
20% pepo 23.74 ± 2.51 30.14 ± 4.32  17.63 ± 1.62
 
ª
 b
 
30% pepo 28.93 ± 3.13  43.20 ± 4.76 ª 25.06 ± 4.83
 
ª 
60% pepo  43.68 ± 7.79
 b
  13.57 ± 2.51 ª
 b
   17.50 ± 1.44
 
ª
 b
 
30% pepo + Xatral 63.46 ± 7.37
 b
 16.58 ± 1.64
 b
 23.14 ± 1.99
 
ª 
 
ª Significant difference (p < 0.05) with respect to the positive control 
b 
Significant difference (p < 0.05) with respect to the negative control 
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3.1. 5- Serum LDL-Cholesterol 
The groups: Xatral (third dissection), 10% pepo (first dissection), 20% pepo, 30% pepo,   
60% pepo, and 30% pepo + Xatral (first, second and third dissection) showed a 
significant decrease in the concentrations of circulating LDL-Cholesterol compared to 
the negative control group. Whereas the groups: Xatral (first and second dissection), and 
10% pepo (second dissection) showed an increase in the concentrations with respect 
also to the negative group. 
On the other hand, there was an increase in the circulating LDL-Cholesterol of the 
groups: Xatral (first dissection), 10% pepo, 20% pepo and 30% pepo (third dissection) 
and a decrease in the groups:  20% pepo and 30% pepo (second dissection), 60% pepo, 
and 30% pepo + Xatral (first, second dissection) compared to the positive group. 
 
Table 3.1.5 LDL-Cholesterol levels in serum after 12, 24 and 36 days consumption of 
different doses of pepo and Xatral in testosterone treated rats. Values denote mean ± 
S.E.M (n = 5) 
LDL – 
Cholesterol 12 Days 24 Days 36 Days 
Negative Control 41.23 ± 1.56 40.16 ± 2.56 40.49 ± 2.74 
Positive Control 32.56 ± 0.35 53.13 ± 9.90 20.35 ± 0.80 
Xatral 56.10 ± 2.88
 a b
 55.10 ± 9.65
 b
 18.20 ± 8.05
 b
 
10% Pepo 29.35 ± 2.74
 b
 55.46 ± 5.55
 b
 36.24 ± 0.43
 a
 
20% Pepo 22.62 ± 1.52
 b
 24.01 ± 3.23
 a b
 40.58 ± 7.43
 a
 
30% Pepo 28.06 ± 2.17
 b
 27.09 ± 0.91
 a b
 32.66 ± 0.30
 a
 
60% Pepo 3.94 ± 2.72
 a b
 13.10 ± 3.46
 a b
 15.91 ± 4.85
 b
 
30% Pepo + Xatral 1.99 ± 2.47
 a b
 21.18 ± 2.01
 a b
 24.81 ± 0.73
 b
 
 
a 
Significant difference (p < 0.05) with respect to the positive control 
b 
Significant difference (p < 0.05) with respect to the negative control 
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3.2- Serum Enzymes  
Tables 3.2.(1, 2, 3) summarizes the serum activities of sGOT-AST, sGPT- AST, and 
ALP in the positive control and groups treated with pumpkin seeds and Xatral for the 
three periods 12, 24, and 36 days.   
 
3.2.1- Serum sGOT-AST 
No significant difference was observed among the negative control groups and all the 
other groups. When compared with the positive control group, there was a significant 
increase in the concentrations of serum GOT between the control group and the groups:  
xatral (first dissection), 60% pepo (third dissection), and the 30% pepo +Xatral (second 
dissection).  
 
 
Table 3.2.1 sGOT-AST activity in serum after 12, 24 and 36 days consumption of 
different doses of pepo and Xatral in testosterone treated rats. Values denote mean 
± S.E.M. (n = 5). 
GOT 12 Days 24 Days 36 Days 
Negative control 9.43 ± 0.51 9.68 ± 0.59  9.72 ± 0.52 
Positive control 10.11 ± 0.44 8.28 ± 0.42 7.78 ± 1.21 
Xatral 14.27 ± 1.38 ª 11.32 ± 2.75 10.58 ± 1.22 
10% pepo 12.25 ± 1.14 7.43 ± 0.67 8.91 ± 086 
20% pepo 10.95 ± 1.18 8.59 ± 0.94 8.98 ± 0.97 
30% pepo 11.74 ± 0.76 7.08 ± 0.39 10.23 ± 0.86 
60% pepo 12.21 ± 1.35 11.01 ± 1.16 11.47 ± 1.09 ª 
30% pepo + Xatral 11.67 ± 1.17 11.32 ± 1.25 ª 10.27 ± 1.45 
 
ª Significant difference (p < 0.05) with respect to the positive control 
b 
Significant difference (p < 0.05) with respect to the negative control 
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3.2.2- Serum sGPT-AST 
There was a significant difference in the groups: Xatral (third dissection), 10% pepo 
(second dissection), 30% pepo (first dissection), 60% pepo and 30% pepo + Xatral 
compared to the negative group. 
When compared to the positive group, a significant increase in the concentration of 
serum GPT was observed in the groups: Xatral (third dissection), 20% pepo (second 
dissection), and 60% pepo (second dissection); and a decrease was observed in the 
groups 60% pepo and 30% pepo +Xatral.  
 
Table 3.2.2 sGPT- AST activity in serum after 12, 24 and 36 days consumption of 
different doses of pepo and Xatral in testosterone treated rats. Values denote mean ± 
S.E.M. (n = 5) 
GPT 12 Days 24 Days 36 Days 
Negative control 5.21 ± 0.19 5.37 ± 0.24 5.41 ± 0.28 
Positive control 8.13 ± 0.67 3.23 ± 0.52
 b
 5.48 ± 0.95 
Xatral 7.16 ± 0.58 6.11 ± 1.37 11.20± 2.07 ª
 b
 
10% pepo 6.27 ± 0.92 4.08 ± 0.74
 b
 5.18± 1.19 
20% pepo 6.29 ± 0.23 5.95 ± 0.72 ª 7.12±0.73 
30% pepo 8.05 ± 0.83
 b
 4.63 ± 0.62 5.95±0.55 
60% pepo 4.95± 0.48 ª
 b
 7.66 ± 1.20 ª
 b
 6.77±0.96 
30% pepo + Xatral 5.72± 0.72 ª 8.94 ± 0.58
 
ª
 b
 7.27±0.71
 b
 
  
ª Significant difference (p < 0.05) with respect to the positive control 
b 
Significant difference (p < 0.05) with respect to the negative control 
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3.2.3- Serum ALP 
A significant difference was observed in the groups: Xatral (first and second dissection), 
10% pepo (third dissection), 20%, 30% and 60% pepo (second and third dissection) and 
30% pepo + Xatral (third dissection) compared to the negative group. 
There was also a significant decrease in the concentration of serum ALP the Xatral 
group (third dissection), 20% pepo (first dissection), 60% pepo and 30% pepo + Xatral 
(first and third dissection) compared to the positive group. 
 
Table 3.2.3 ALP activity in serum after 12, 24 and 36 days consumption of different 
doses of pepo and Xatral in testosterone treated rats. Values denote mean ± S.E.M.  
(n = 5) 
ALP 12 Days 24 Days 36 Days 
Negative control 50.52 ± 1.72 51.17 ± 1.62 49.50 ± 1.94 
Positive control 36.96 ± 3.38 50.38 ± 8.49 29.63 ± 3.46 
Xatral 36.74 ± 2.29
 b
 39.75 ± 4.44
 b
 42.46 ± 3.62 ª 
10% pepo 45.17 ± 2.43 48.69 ± 5.91 33.00 ± 3.96
 b
 
20% pepo 50.20 ± 4.47 ª 68.27 ± 11.31
 b
 44.29 ± 6.36 
30% pepo 45.32 ± 4.25 69.67 ± 9.92
 b
 39.09 ± 4.41
 b
 
60% pepo 51.55 ± 2.59 ª 41.73 ± 6.69
 b
 53.97 ± 5.95 ª 
30% pepo + Xatral 58.08 ± 1.44
 
ª 48.69 ± 5.72 41.87 ± 1.35 ª
 b
 
 
ª Significant difference (p < 0.05) with respect to the positive control 
b 
Significant difference (p < 0.05) with respect to the negative control 
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3.3- Evaluation of prostate enlargement 
3.3.1- Prostate weights 
Significant elevation in prostate weights was found with testosterone treatment when 
compared with negative control rats. On the other hand there was significant reduction 
in elevation of prostate weights of groups treated with pumpkin seeds in testosterone 
treated rats.  
 
3.3.2- Prostate weights to body weights ratio 
Testosterone significantly elevated the prostate weights/body weights ratio when 
compared with negative control rats. But significant reduction in elevation of prostate 
weights/body weights ratio was found by pumpkin seeds treatment in testosterone 
treated rats.  
During the first 12 days, the groups VI (30% pepo), VII (60% pepo), and VIII (30% 
pepo + Xatral) showed the highest % of inhibition especially the group VI which was 
inhibited 86.7%. 
During the second dissection (24 days), the same results were observed especially the 
group 30% pepo that was also inhibited 98%. 
The same observation was noticed in the final dissection after 36 days where group VI 
(30% pepo) was inhibited 98.4%. In addition group 10% showed 84.91% of inhibition. 
 
3.3.3- Body weights changes 
There were no significant differences in body weights of rats before and after 
testosterone treatment among groups.  
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Table 3.3.1 Effect of pumpkin seeds and Xatral on body weights and prostate 
enlargements in testosterone treated rats during the first twelve days. Values denote 
mean ± SEM (n=5) 
Groups BW(g) PW(g) PW/BW ratio(103) 
% 
inhibition 
Group I 374.66 ± 19.61 0.800 ± 0.063 2.135 ± 0.000138 
b 
 
Group II 300.00  ± 9.24 0.493 ± 0.013 1.652 ± 0.000086 
a 
 
Group III 338.22 ± 16.29 0.707 ± 0.021 2.100 ± 0.000057
  b
 7.18% 
b
 
Group IV 342.14 ± 25.06 0.687 ± 0.036 2.048 ± 0.000181
  b
 18.02% 
b
 
Group V 361.82 ± 26.24 0.728 ± 0.050 2.025 ± 0.000114
  b
 22.71% 
b
 
Group VI 387.00 ± 10.87 0.664 ± 0.050 1.716 ± 0.000119 
a
 86.70% ª 
Group VII 355.80 ±  8.67 0.635 ± 0.065 1.783  ±  0.000163 
a
 72.84% ª 
Group VIII 312.00 ± 13.47 0.566 ± 0.009 1.826 ± 0.000067
 a
 63.90% ª 
 
 PW: Prostate weight, BW: Body weight, Group I: Positive control, Group II: 
Negative Control, Group III: Xatral, Group IV: 10% Pepo, Group V: 20% Pepo, 
Group VI: 30% Pepo, Group VII: 60% Pepo, Group VIII: 30% + Xatral. Values 
are expressed as mean ± S.E.M. 
ª Significant difference (p < 0.05) with respect to the positive control 
b
 Significant difference (p < 0.05) with respect to the negative control 
 Chart 3.1.1 Ratio of prostate weight over body weight during the first twelve days. 
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Chart 3.1.2 Percentage inhibition during the first twelve days. 
 
ª Significant difference (p < 0.05) with respect to the positive control 
b
 Significant difference (p < 0.05) with respect to the negative control 
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Table 3.3.2 Effect of pumpkin seeds and xatral on body weights and prostate 
enlargements in testosterone treated rats during twenty four days. Values denote mean ± 
SEM (n=5) 
Groups BW(g) PW(g) PW/BW ratio(103) 
% 
inhibition 
Group I 325.00 ± 7.96 0.805 ± 0.027 2.477 ± 0.198
 b
  
Group II 322.80 ± 20.66 0.550 ± 0.037 1.711 ± 0.086 ª  
Group III 307.00 ± 21.07 0.744 ± 0.023 2.475 ± 0.198
 b
 0.25% 
b
 
Group IV 292.40 ± 29.60 0.641 ± 0.031 2.250 ± 0.171
 b
 29.59% 
b
 
Group V 344.20 ± 13.11 0.680 ± 0.025 1.981 ± 0.073
 b
 64.76% 
b
 
Group VI 400.20 ± 13.31 0.690 ± 0.059 1.726 ± 0.146 ª 98.00% ª 
Group VII 331.00 ± 7.05 0.571 ± 0.021 1.728 ± 0.064 ª 97.74% ª 
Group VIII 329.20 ± 9.14 0.569 ± 0.031 1.727 ± 0.064 ª 97.88% ª 
 
 PW: Prostate weight, BW: Body weight, Group I: Positive control, Group II: 
Negative Control, Group III: Xatral, Group IV: 10% Pepo, Group V: 20% Pepo, 
Group VI: 30% Pepo, Group VII: 60% Pepo, Group VIII: 30% + Xatral. Values 
are expressed as mean ± S.E.M 
ª Significant difference (p < 0.05) with respect to the positive control 
b
 Significant difference (p < 0.05) with respect to the negative control 
Chart 3.2.1 Ratio of prostate weight over body weight during the twenty four days. 
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Chart 3.2.2 Percentage inhibition during the twenty four days. 
 
ª Significant difference (p < 0.05) with respect to the positive control 
b
 Significant difference (p < 0.05) with respect to the negative control 
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Table 3.3.3 Effect of pumpkin seeds and xatral on body weights and prostate 
enlargements in testosterone treated rats during thirty six days. Values denote mean ± 
SEM (n=5). 
Groups BW(g) PW(g) PW/BW ratio(103) 
% 
inhibition 
Group I 322.20 ± 23.18 0.749 ± 0.053 2.338 ± 0.070
 b
  
Group II 297.00 ± 14.90 0.543 ± 0.026 1.833 ± 0.064
 
ª  
Group III 285.20 ± 10.02 0.655 ± 0.022 2.301 ± 0.070
 b
 7.32% 
b
 
Group IV 370.20 ± 16.97 0.705 ± 0.052 1.909 ± 0.129 ª 84.91% ª 
Group V 339.20 ± 29.83 0.693 ± 0.074 2.049 ± 0.178
 b
 57.25% 
b
 
Group VI 322.20 ± 16.85 0.590 ± 0.018 1.841 ± 0.060 ª  98.43% ª 
Group VII 372.60 ± 17.19 0.686 ± 0.041 1.843 ± 0.091 ª 97.85% ª 
Group VIII 360.20 ± 19.24 0.658 ± 0.016 1.843 ± 0.086 ª 98.02% ª 
 
 PW: Prostate weight, BW: Body weight, Group I: Positive control, Group II: 
Negative Control, Group III: Xatral, Group IV: 10% Pepo, Group V: 20% Pepo, 
Group VI: 30% Pepo, Group VII: 60% Pepo, Group VIII: 30% + Xatral. Values 
are expressed as mean ± S.E.M 
ª Significant difference (p < 0.05) with respect to the positive control 
b
 Significant difference (p < 0.05) with respect to the negative control 
Chart 3.3.1Ratio of prostate weight over body weight during the thirty six days. 
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Chart 3.3.2 Percentage inhibition during the thirty six days. 
 
ª Significant difference (p < 0.05) with respect to the positive control 
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3.3.4- Histopathology of prostate  
The prostate glands were removed and preserved in 10% formaldehyde. Biopsies were 
later processed to end up with slides representing all the samples. Slides were then 
stained to highlight the differences between the control and treated groups. Figure 3.4 
shows the prostate gland of a rat that had no histopathological signs. The glandular cells 
are lined by epithelial cells that show mild convolutions. So the tissues were tightly 
packed; epithelium was cuboidal and regular in size. There is abundant stroma in 
between glands. 
 
 
 
Figure 3.1 Negative group showing no histopathological signs (10x). 
Glandular 
cells 
Stroma 
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Figure 3.5 shows the prostate gland of the group having BPH. There was disruption in 
the histoarchitecture of the prostate tissue. Here the glandular cells are crowded with 
only little intervening stroma. In addition those cells are lined by high convoluted 
epithelium showing intraluminal papillary projections. 
 
 
 
Figure 3.2 Positive group having BPH (10x). 
 
Intraluminal 
papillary 
projections of 
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This figure shows the group that has BPH and treated with 30% w/w pepo. It shows a 
reduction in histoarchitecture disruption of the prostate compared to the positive control 
group. So the appearance is similar to the negative control group. There is abundant 
stroma between the glandular cells. In additions there is a lack of papillary projections 
into the lumen of those glands. 
 
  
 
 
Figure 3.3 Group treated with 30% w/w pepo (10x). Glands with abundant stroma in 
between. Lack of papillary projections into the lumen of glands.  
 
Glandular cells 
Stroma 
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All slides representing the experimental groups are presented in figure 3.7 to facilitate 
the comparison between the different groups concerning the morphological features 
discussed before. 
 
  
A B 
 
C 
 
Figure 3.4 A: negative control, B: positive control, C: testosterone + 30% pepo. 
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CHAPTER FOUR 
DISCUSSION AND CONCLUSION 
 
The present study focuses on assessing the effects of pumpkin seeds on benign prostatic 
hyperplasia which is induced by testosterone. The decrease in prostate enlargement was 
shown by a reduction in prostate weight to body weight ratio compared to normal rat.  
Lipid profile test (glucose, triglycerides, cholesterol and HDL-cholesterol) and liver 
enzymes test, GOT-AST, GPT-AST; and ALP) were determined in order to assess 
possible secondary effects of the pumpkin seeds. The present study was conducted on 
the male rats in order to avoid any possible toxic effect in human. Chronic human 
studies are conflicted by differences such as liver function, nutritional factors, smoking, 
physical activity, and other confounding factors. Thus, animals’ studies are easier to 
control.  
In this study, pumpkin seeds appear to have a significant effect on blood lipid profile. 
First serum glucose concentrations were increased in all groups injected with 
testosterone (p<0.05). This increase in blood sugar level is due to testosterone treatment 
as previously shown in several investigations (Caili et al., 2006). This hyperglycemic 
level was not reduced by ungerminated pumpkin seeds except for the group 20% pepo, 
and 30% pepo (third dissection). Studies show that proteins from germinated pumpkin 
seeds after 4 days of germination reduce hyperglycemia by increasing the level of blood 
insulin; whereas the ungerminated seed didn’t possess any effect (Caili et al., 2006). 
On the other hand there is a decrease in the concentrations of the circulating TAG 
compared to the positive control. Whereas no important significant difference was 
observed compared to the negative controls. So all groups returned to the normal criteria 
range during treatment with pepo after the first dissection. 
Similarly the concentration of the total cholesterol and HDL cholesterol were also kept 
in the normal range such as the value of the negative control; whereas the groups 60% 
pepo and 30% pepo+Xatral, show a decrease in the concentration more than the normal 
value, so we can conclude that those doses affect negatively the amount of total and 
HDL cholesterol. As for the decrease that appears for the group 20% pepo (third 
dissection), this could be related to the long term treatment. 
Concerning the concentration of LDL-Cholesterol, results showed that pumpkin seeds 
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reduce the concentration more than the normal value. On the other hand, Xatral 
increased the concentration of LDL-Cholesterol for short term treatment.  In addition, 
the groups 60% and 30% Xatral showed a high decrease in the amount of circulating 
LDL-cholesterol. So as the concentration of pumpkin seeds increase the concentration 
of LDL-cholesterol decrease more and more. This is also confirmed by a study that 
show that foods containing high concentrations of unsaturated fatty acids such as 
linoleic acid and oleic acid and plants sterols decrease serum LDL cholesterol by 
increasing the excretion of cholesterol from the bowl and reducing cholesterol 
absorption. So plants sterols reduce serum cholesterol and are protective for individuals 
having heart diseases (Ellegard, Andersson, Normen & Andersson, 2007). 
On the other hand, there was no significant difference in the amount of sGOT-AST 
enzyme when treating with the different doses of pumpkin seeds. Whereas for SGPT-
AST enzyme that is produced by the liver the abnormal value attained by the positive 
control returned to the normal value when treating with the different percentage of 
pumpkin seeds except for the groups 60% and 30% Xatral that show also some toxicity 
on the Liver enzyme. The concentration of this enzyme in those groups increase more 
than the normal value. Concerning ALP, the decrease attained by the positive control 
returned to the normal value for the groups treated with the different doses of pumpkin 
seeds whereas for the groups treated with Xatral the amount remain as the positive 
control. It was important to examine the differences in the gained weights between the 
groups. It was shown from all the groups tested that neither testosterone nor pumpkin 
seeds administration had any influence on the weight gain of the rats, so the weight gain 
between the groups and for the three different dissections was similar. Hyperplasia of 
the prostate rats was induced with testosterone. This is due to the fact that the hormone 
is responsible for the development of BPH. Then the value of the prostate size of these 
rats was compared to the value of the negative control group. It was established that the 
enzyme 5α-reductase that is found in the epithelial cells of the prostate and more 
precisely in the nuclear membrane, converts testosterone to dihydrotestosterone (DHT) 
which is responsible for the development of BPH. A reduction in the formation of the 
enzyme 5α-reductase will induce a decrease in the concentration of DHT. This 
inhibition will not affect the sexual function of the body since they only inhibit the 
formation of DHT (Veeresh Babu, Veeresh, Patil & Warke, 2010). Moreover, the 
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protein cucurbitacins that are found in pumpkin seeds inhibit the activity of 5α-
reductase (Thomas, 1999).  It was also shown in the same study that many plants such 
as saw palmetto, coconut, Serenoa repens and pumpkin seeds are responsible for the 
inhibition of BHP due to the presence of fatty acids in their active ingredients (Veeresh 
Babu et al., 2010). Another study showed that the extract of saw palmetto is similar in 
action to finasteride in the improvement of the urinary tract symptoms and the flow of 
the urine for short term treatment (Wilt et al., 1998). Moreover, pumpkin seeds in 
conjunction with saw palmetto seeds extract are used against benign prostatic 
hyperplasia (Abdel-Rahman, 2006). 
The ratio of prostate weight over body weight has been used as the main marker for the 
treatment. This treatment had no effect on the body weight gain but it had a high effect 
on the prostate weight over body weight gain. It was noticed that BPH was less in rats 
given simultaneously testosterone with pumpkin seeds, and this protection is significant 
when the pumpkin seeds dose was 30% and 30% + Xatral  in the first 12 days of 
treatment. After 24 days, the inhibitions increase more and more and it reached 98% for 
the group 30% pepo. For long term treatment, or after 36 days, a reduction appeared in 
the group 10% and 30% pepo. This result is also confirmed by the histopathological 
studies that showed that the group treated with 30% w/w pepo had the same appearance 
as the negative control. There is abundant stoma between glandular cells. In addition 
there is lack of papillary projections into the lumen of the glands. 
Also during all period of treatment a decrease in PW/BW ratio appeared also for the 
group 60% and 30% + Xatral. But those percentages showed some negative effects on 
the lipid profile and liver enzyme. That’s why we can consider that the 30% pumpkin 
seeds is the suitable dose for short treatment. For long term treatment we have the 
effectiveness of the groups’ 10% and 30% w/w pepo.  
A study done by Abdel-Rahman (2006), showed also that pumpkin seeds at 10% 
inhibited BPH by decreasing the level of protein binding prostate (PBP); and decreasing 
the prostate weight. He noticed that pumpkin seeds, that are rich in omega 3, 6 and 9 
that are unsaturated fatty acids and their high protein content, reduce protein binding 
prostate tissues, and this will lead to a reduction of BPH. Moreover, he established that 
pumpkin seeds are not only effective in reducing the symptoms of BPH in its early stage 
but there are no significant side effects. However, in the present study, the dose 10% 
 48 
appears to reduce prostate weight after long term treatment but not as much as the dose 
30%. The histopathological study didn’t confirm this result; the appearance of the 
prostate treated with group 10% remains similar to the positive control whereas the 
group treated with 30% pepo is similar to the negative control group. 
Many studies show that the active ingredients of pumpkin seeds interrupt the 
multiplication of the prostate cell induced by testosterone.  First, it is shown that the ∆7- 
phytosterols together with their glycosides that is found in the pumpkin seed oil inhibit 
the action of the enzyme 5α-reductase because there is a conformative similarity 
between testosterone and ∆7- phytosterols. As a result the symptoms of prostate 
hypertrophy are reduced due to the competition between both at the same receptor 
(Mandl et al., 1999). 
Also the vitamins that are found in pumpkin seeds play an important role in reducing 
BPH. Among them vitamin E succinate inhibits the proliferation of several cancer cells 
by arresting the synthesis of the DNA of cancerous cells or by the stimulation of the 
transforming growth factor beta (TGF-β) (Zhang et al., 2002). 
Since the amount of Zinc decreases in prostatitis and prostate cancer, pumpkin seeds 
that contain Zinc reduce the size of the developed prostate (Lagiou et al., 1999).  Leake 
et al (1984), showed that Zinc has also a modulator role on the activity of 5α-reductase 
of prostate gland of the human. They showed that Zinc play a physiological role in the 
regulation of testosterone metabolism. This hormone which is converted to DHT by the 
NADPH dependent enzyme 5α-reductase is an important step in the prostate gland to 
express the androgenic responses. It was shown that Zinc regulates this conversion, but 
it remained unknown whether this metal acts on the 5α-reducase directly or on the 
generation of the cofactor NADPH. 
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CONCLUSION 
 
The oral administration of pumpkin seed is useful in the treatment of benign prostatic 
hyperplasia (BPH) induced by testosterone in male Sprague-Dawley rats. Pumpkin 
seeds at 30% w/w can alleviate the signs of BPH such as decrease in the weight of the 
prostate, and improvement of the histology of this gland. In addition, this dose is 
beneficial because there are no negative effects concerning the lipid profile tests and 
liver enzyme tests. 
Further experimental studies are necessary to verify the present study to be able to 
decide whether this dose is meaningful to human having benign prostatic hyperplasia 
without any complication as it was shown. In addition further recommendations are 
required to identify the relation between pumpkin seed and prostate cancer. 
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GLOSSARY 
A: Androsterone  
Abs: Absorbance 
Ad lib: Ad libitum 
ALP: Alkaline phosphatase 
ALT: Alanine aminotransferase  
AST: Aspartate aminotransferase  
BPH: Benign prostatic hyperplasia 
BW: Body weight 
C. pepo : Cucurbita Pepo 
CHE : Cholesterol esterase 
Conc : Concentration 
cPSA : Complex prostate specific antigen 
DHT: Dihydrotestosterone  
DRE: Digital rectal examination  
E: Etiocholanolone  
ER: Extended-release 
FA: Fatty acid 
GK: Glycerol Kinase  
GOD: Glucose oxidase 
GOT: Glutamate oxaloacetate  
GPO: Glycerol-3-Phosphate Oxidase  
GPT: Glutamate pyruvate transaminase 
HDL: High density lipoprotein 
HoLEP: Holmium laser enucleation of prostate  
IR: immediate-release  
LDH: Lactate dehydrogenase 
LDL: Low Density Lipoprotein 
LPL: Lipoprotein lipase 
LUTS: Lower urinary tract symptoms  
MDH: Malate dehydrogenase  
NIDDM : Non-insulin dependent diabetes mellitus 
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PAS: Periodic Acid Shicff  
POD: Peroxidase 
PSA: Prostate specific antigen 
PSAD: Prostate specific antigen density 
PW: Prostate weight 
SEM: Standard error from the mean 
sGOT: Serum glutamic oxaloacetic transaminase 
sGPT: Serum glutamic pyruvic transaminase 
TAG: Triacylglycerol 
TGF-β: Transforming growth factor beta  
T-P: Testosterone prazosin 
TUIP: Transurethral incision of the prostate  
TURP: Transurethral resection of the prostate  
UTI: Urinary tract infections  
VLDL: Very low density lipoprotein  
5 α-Reductase: 5alpha-reductase 
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